VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered class-leading Phase 1 results including ...

The cloud IT vendor said it now gives patients a no-login, digital identity-based access system to exercise greater control ...

Multidrug-resistant bacteria kill five million people each year, with newly resistant germs emerging faster than scientists ...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today ...

BACKGROUND: Whether cannabis is a risk factor for cardiovascular events is unknown. We examined the association between smoking cannabis and cardiovascular events in a cohort of older veterans (66 to ...

AbCellera's AI-driven drug discovery model hasn't translated into meaningful growth. Click here to read an analysis of ABCL ...

Some of the most interesting data are precisely those illustrating the reality of clinical practice of physicians attending ...

This allowed both the doctors and the AI system to ask questions and make decisions about next steps, such as ordering tests, based on the information they learned at each step—similar to a flow chart ...

Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...

A new platform designed by Meditrax allows real-time connection of RMMRs to My Health Record, boosting continuity of care ...

"No UPCODE Act" Jeopardizes Florida's Medicare Advantage Success Florida is home to the second-highest number of Medicare ...